1. High–Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome
- Author
-
Kenneth W. Tsang, Johnny W.M. Chan, Ivan Hung, Moira Chan-Yeung, Poon Chuen Wong, Wah K. Lam, Thomas Y.W. Mok, James Chung-Man Ho, Mary S. Ip, Pak L. Ho, Bing Lam, Gaik C. Ooi, Chun K. Ng, Patrick C.K. Li, and Kar N. Lai
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.drug_class ,Secondary infection ,medicine.medical_treatment ,Anti-Inflammatory Agents ,Severe Acute Respiratory Syndrome ,Critical Care and Intensive Care Medicine ,Antiviral Agents ,Methylprednisolone ,law.invention ,Cohort Studies ,law ,Intensive care ,Ribavirin ,medicine ,Humans ,Aged ,Retrospective Studies ,Mechanical ventilation ,business.industry ,Middle Aged ,medicine.disease ,Intensive care unit ,Surgery ,Regimen ,Treatment Outcome ,Pulse Therapy, Drug ,Atypical pneumonia ,Anesthesia ,Corticosteroid ,Female ,business ,medicine.drug - Abstract
The treatment of atypical pneumonia, subsequently termed severe acute respiratory syndrome (SARS), is controversial, and the efficacy of corticosteroid therapy is unknown. We have evaluated the clinical and radiographic outcomes of 72 patients with probable SARS (median age 37 years, 30 M), who received ribavirin and different steroid regimens in two regional hospitals. Chest radiographs were scored according to the percentage of lung field involved. Seventeen patients initially received pulse steroid (PS) (methylprednisolone > or =500 mg/day) and 55 patients initially received nonpulse steroid (NPS) (methylprednisolone
- Published
- 2003
- Full Text
- View/download PDF